WINDWARD BIO GROUP AG

Show
8-K events
Match any selected event
8-K event types
More events

Only filters 8-Ks. Other selected forms stay visible.

Industries

What it sells; a bar is that business's share of revenue.

  • biopharmaSells it: a product, service or segment of its own.From the prospectus: “We are a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, including asthma, COPD, and atopic dermatitis.”All companies in biopharma →

Themes

Trends it takes part in: by selling, supplying, using or developing. A share is the revenue of the lines that are mostly that theme.

  • respiratory diseasepipelineIn development or planned, with no sales yet.From the prospectus: “WIN378 is initially being developed for the treatment of respiratory diseases with a focus on asthma and COPD.”All companies in respiratory disease →
  • inflammatory diseasepipelineIn development or planned, with no sales yet.From the prospectus: “Our mission is to transform the treatment paradigm for patients living with chronic inflammatory diseases through the development of differentiated biologic therapies targeting validated disease pathways.”All companies in inflammatory disease →

Exposures

Outside forces the filing says could move its results.

  • clinical trial riskNamed in the filing as something outside the company that could move its results.From our summary of the prospectus: “Trials may fail efficacy or safety endpoints, reveal adverse events, enroll slowly, or require additional studies.”All companies in clinical trial risk →
  • funding availabilityNamed in the filing as something outside the company that could move its results.From our summary of the prospectus: “Further capital will be needed; unavailable or unfavorable financing could force delays, reductions, or termination of programs.”All companies in funding availability →
  • licensor dependenceNamed in the filing as something outside the company that could move its results.From our summary of the prospectus: “WWB relies on data, development work, and rights from licensors Kelun and HBM for WIN378 and Qyuns for WIN027.”All companies in licensor dependence →
  • chinaNamed in the filing as something outside the company that could move its results.From our summary of the prospectus: “PRC-related policy, geopolitical, export-control, sanctions, or data-transfer restrictions could disrupt access to data, technology, materials, manufacturing, or support.”All companies in china →
  • drug pricing regulationNamed in the filing as something outside the company that could move its results.From our summary of the prospectus: “Evolving U.S. and EU drug-pricing, reimbursement, and health-technology-assessment policies add uncertainty.”All companies in drug pricing regulation →

From the IPO prospectus (424B4) filed Nov 13, 2026, before the company's first 10-K.

Feedback